Pre-Session Views

Strategy | We are buyers of every dip in Memphis PharmaWe are buyers of every dip in Memphis PharmaRAYA/RACC | RAYA/RACC acquisition is now most likely to go through at RAYA’s revised price of EGP9.0/share, exactly at the midpoint of our previously communicated price rangePHAR | EIPICO III delay extends visibility gap, rotation toward MPCI and RMDAAMOC | Shareholder rotation reflects profitability headwindsEGAL | Riding the aluminum wave